Modern Prodrug Design for Targeted Oral Drug Delivery

被引:56
|
作者
Dahan, Arik [1 ]
Zimmermann, Ellen M. [2 ]
Ben-Shabat, Shimon [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Pharm, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel
[2] Univ Florida, Div Gastroenterol, Dept Med, Gainesville, FL 32608 USA
来源
MOLECULES | 2014年 / 19卷 / 10期
关键词
molecular biopharmaceutics; membrane transporters; passive/active intestinal permeability; prodrug activation; targeted prodrug approach; IN-VITRO EVALUATION; L-VALYL ESTER; AMINOMETHYL)-1-CYCLOHEXANE ACETIC-ACID; INTESTINAL LYMPHATIC TRANSPORT; ORGANIC CATION TRANSPORTERS; INFLAMMATORY-BOWEL-DISEASE; WILD-TYPE; ACTIVATING ENZYME; TESTOSTERONE UNDECANOATE; SUBSTRATE-SPECIFICITY;
D O I
10.3390/molecules191016489
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular information that became available over the past two decades significantly influenced the field of drug design and delivery at large, and the prodrug approach in particular. While the traditional prodrug approach was aimed at altering various physiochemical parameters, e. g., lipophilicity and charge state, the modern approach to prodrug design considers molecular/cellular factors, e. g., membrane influx/efflux transporters and cellular protein expression and distribution. This novel targeted-prodrug approach is aimed to exploit carrier-mediated transport for enhanced intestinal permeability, as well as specific enzymes to promote activation of the prodrug and liberation of the free parent drug. The purpose of this article is to provide a concise overview of this modern prodrug approach, with useful successful examples for its utilization. In the past the prodrug approach used to be viewed as a last option strategy, after all other possible solutions were exhausted; nowadays this is no longer the case, and in fact, the prodrug approach should be considered already in the very earliest development stages. Indeed, the prodrug approach becomes more and more popular and successful. A mechanistic prodrug design that aims to allow intestinal permeability by specific transporters, as well as activation by specific enzymes, may greatly improve the prodrug efficiency, and allow for novel oral treatment options.
引用
收藏
页码:16489 / 16505
页数:17
相关论文
共 50 条
  • [31] Prodrug strategies in nasal drug delivery
    Pezron, I
    Tirucherai, GS
    Duvvuri, S
    Mitra, AK
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (03) : 331 - 340
  • [32] Colonic drug delivery: Prodrug approach
    Sinha, VR
    Kumria, R
    PHARMACEUTICAL RESEARCH, 2001, 18 (05) : 557 - 564
  • [33] PRODRUG APPROACH IN IMPROVING DRUG DELIVERY
    SHARMA, PD
    JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH, 1986, 45 (12): : 534 - 543
  • [34] Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells
    Zhou, Ru
    Zhang, Mingzu
    He, Jinlin
    Liu, Jian
    Sun, Xingwei
    Ni, Peihong
    ACS OMEGA, 2022, 7 (24): : 21325 - 21336
  • [35] Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
    Jana, S.
    Mandlekar, S.
    Marathe, P.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (32) : 3874 - 3908
  • [36] Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy
    Faustino, Celia
    Duarte, Noelia
    Pinheiro, Lidia
    PHARMACEUTICALS, 2024, 17 (01)
  • [37] Enabling Oral Amphotericin B Delivery by Merging the Benefits of Prodrug Approach and Nanocarrier-Mediated Drug Delivery
    Thanki, Kaushik
    Date, Tushar
    Jain, Sanyog
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2021, 9 (06) : 2879 - 2890
  • [38] Prodrug technology in drug design
    Niemi, Riku
    Taipale, Hannu
    Jarvinen, Tomi
    (24):
  • [39] Development of an Innovative Dual Construct for Targeted Drug Delivery in the Oral Cavity
    Mazzinelli, Elena
    Favuzzi, Ilaria
    Messina, Marianna
    Fratocchi, Giorgia
    Vincenzoni, Federica
    Stefano, Eleonora Santo
    Cecconi, Francesco
    Lajolo, Carlo
    Basco, Alessia
    Castagnola, Raffaella
    Cordaro, Massimo
    Scilla, Francesco
    Papa, Valerio
    Arcovito, Alessandro
    Cacciotti, Ilaria
    Nocca, Giuseppina
    PHARMACEUTICS, 2025, 17 (02)
  • [40] Targeted drug delivery system for oral cancer therapy using sonoporation
    Maeda, Hironobu
    Tominaga, Kazuhiro
    Iwanaga, Kenjiro
    Nagao, Fuminori
    Habu, Manabu
    Tsujisawa, Toshiyuki
    Seta, Yuji
    Toyoshima, Kuniaki
    Fukuda, Jin-ichi
    Nishihara, Tatsuji
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2009, 38 (07) : 572 - 579